Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 1/8/2007 First Published: 8/1/2002


1.		Phase III Randomized Study of Calcium and Cholecalciferol With or Without Conjugated Estrogens and With or Without Risedronate for the Prevention of Osteoporosis in Patients With Prostate Cancer Receiving Androgen-Ablation Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				NCI				NCCTG-N01C8 NCI-P02-0229, N01C8, NCT00043069

Last Modified: 11/27/2006 First Published: 1/26/2003


2.		Phase III Randomized Study of Risedronate For Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy For Primary Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				NCI				NCCTG-N02C1 N02C1, NCT00054418


3.		Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Completed				Postmenopausal				Pharmaceutical / Industry				D5392C00050 SABRE, NCT00082277

Last Modified: 6/2/2008 First Published: 7/14/2006


4.		Phase III Companion Study of Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Treated on Protocol CAN-NCIC-MA27

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Natural history/Epidemiology, Supportive care				Closed				45 and over				NCI				CAN-NCIC-MA27B NCIC-MA.27B, SWOG-NCIC-MA27B, NCCTG-NCIC-MA27B, CAN-NCIC-BONE, NCT00354302, MA27B


5.		Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				18 and over				Other				SA-CMX-01 NCT00426777

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute